drugset / Trial / NCT03723148
Individual Patient Compassionate Use of Fedratinib
Expanded access
Available
Celgene Corporation
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation · collab
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fedratinib | Small molecule | — | Oral |